Abstract： Objective： To observe the effect of Yiqi Huoxue Yangxin Decoction on the inflammatory factors，heart function and prognosis of patients with acute ST-elevation myocardial infarction (ASTEMI) in early stage. Methods： A total of 68 ASTEMI patients were retrospectively selected as the study subjects and divided into the control group and the observation group according to different treatment methods， with 34 cases in each group. The control group was given earlier thrombolysis，and the observation group was treated with Yiqi Huoxue Yangxin Decoction based on the treatment of the control group. The clinical effects， recovery of coronary artery， incidence of adverse reactions， and the changes of inflammatory factors， including prostaglandin E2 (PGE2)， interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP)，indexes of heart function，including left ventricular ejection fraction (LVEF)，left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV)，and traditional Chinese medicine (TCM) symptom scores were compared before and after treatment between the two groups. Results：The total effective rate was 94.12% in the observation group and 76.47% in the control group， the difference being significant (P＜0.05). After treatment of 48 hours， the levels of PGE2， IL-6 and hs-CRP in both groups were decreased when compared with those before treatment (P＜0.05)，and the above levels in the observation group were lower than those in the control group (P＜0.05). After two weeks of treatment，the LVEF levels in the two groups were increased when compared with those before treatment (P＜0.05)，and the levels of LVEDV and LVESV were decreased when compared with those before treatment (P＜0.05)； the LVEF level in the observation group was higher than that in the control group (P＜0.05)，and the levels of LVEDV and LVESV were lower than those in the control group (P＜0.05). After two weekst of reatment， the TCM symptom scores in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above scores in the observation group were lower than those in the control group (P＜ 0.05). After two weeks of treatment， the number of patients with decrease in ST segment and platelet aggregation rate in the observation group was more than that in the control group， the difference being significant (P＜0.05). There was no significant difference being found in the comparisons of reperfusion arrhythmia， premature peak value of myocardial enzyme and patency of coronary artery between the two groups (P＞0.05). The incidence of adverse reactions was 8.82% in the observation group and 23.53% in the control group， the difference being significant (P＜0.05). Conclusion： Yiqi Huoxue Yangxin Decoction enhance the clinical effect on ASTEMI patients receiving earlier thrombolysis， which can reduce the inflammatory responses and mitigate the clinical symptoms with good medication safety and prognosis.